What's new? Log in Free sign up

Inhibikase Therapeutics (IKT) News and press releases

Company Profile

News

From Benzinga Pro

Inhibikase Therapeutics Q1 EPS $(0.16) Misses $(0.14) Estimate, Sales $64.52K Up From $46.03K YoY

Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.14) by 14.29 percent. This is a 11.11 percent increase over losses of $(0.18) per

Earnings Scheduled For May 15, 2023

Companies Reporting Before The Bell • Caledonia Mining (AMEX:CMCL) is expected to report earnings for its first quarter. • Sohu.com (NASDAQ:SOHU) is projected to report earnings for its first quarter.

Earnings Preview: Inhibikase Therapeutics

Benzinga's Top Ratings Upgrades, Downgrades For April 18, 2023

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

HC Wainwright & Co. Initiates Coverage On Inhibikase Therapeutics with Buy Rating, Announces Price Target of $5

News, Price Target, Initiation, Analyst Ratings

HC Wainwright & Co. analyst Edward White initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Buy rating and announces Price Target of $5.

Earnings Scheduled For March 31, 2023

Companies Reporting Before The Bell • Pioneer Muni High Inc (NYSE:MAV) is likely to report quarterly earnings at $0.05 per share on revenue of $35.00 million.

Inhibikase Therapeutics Provides Interim Update On The '501' Bioequivalence Study Of IkT-001Pro

Biotech, News, FDA, General

Completed dosing of 3 of 4 planned cohorts; expect to complete study in the second quarter of 2023 BOSTON and ATLANTA, March 15, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc.

Why RAPT Therapeutics Shares Are Trading Lower By Over 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

Gainers Ainos, Inc. (NASDAQ: AIMD) shares jumped 69.3% to $1.27 after the company announced it signed a Memorandum of Understanding with Merdury Biopharmaceutical to jointly explore and develop a strategic business relationship.

Press releases

From Benzinga Pro

Inhibikase Therapeutics to Present at the LD Micro Invitational XIII

BOSTON and ATLANTA, May 30, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor

Inhibikase Therapeutics: A Novel And Promising Approach To Neurodegeneration And Oncology

IKT's heavily discounted valuation provides a compelling risk/reward given the ability to establish both safety and efficacy in Parkinson's disease let alone any progress in oncology.New York, NY--News

Inhibikase Therapeutics Announces Dosing of First Patient in its Phase 2 '201' Clinical Trial of IkT-148009 to Treat Parkinson's Disease

BOSTON and ATLANTA, May 16, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease

Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity

Earnings, Press Releases

Company to host conference call on Tuesday, May 16, 2023 at 8:00 a.m. ET BOSTON and ATLANTA, May 15, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase or Company), a clinical-stage

Inhibikase Therapeutics to Report First Quarter Financial Results on May 15, 2023

BOSTON and ATLANTA, May 8, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor

Inhibikase Therapeutics to Present at the Sidoti Micro-Cap Virtual Conference

BOSTON and ATLANTA, May 4, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor

Inhibikase Therapeutics Provides Safety and Functional Update on its Phase 1/1b 101 Trial and its Phase 2 IkT-148009 201 Trial in Parkinson's Disease

- State-of-the-art biomarker analyses a hallmark of the 201 study - BOSTON and ATLANTA, April 26, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase or Company), a clinical-stage pharmaceutical

Inhibikase Therapeutics to Present at the 2023 Planet MicroCap Showcase

BOSTON and ATLANTA, April 21, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor

Inhibikase Therapeutics Reports Full Year 2022 Financial Results and Highlights Recent Period Activity

Earnings, Press Releases

BOSTON and ATLANTA, March 31, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify

Inhibikase Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results on March 31, 2023

BOSTON and ATLANTA, March 23, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor

Inhibikase Therapeutics to Host Virtual R&D Event on March 22, 2023

BOSTON and ATLANTA, March 16, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor

Shares Of Inhibikase Therapeutics Stock Decouples From NASDAQ Weakness; Jump 8% Including A/H Wednesday As Interest In Ikt-148009 Intensifies ($IKT)

News, Press Releases

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) stock gained on Wednesday despite another bearish day in the broader markets, moving higher by about 3% and, at press time, adding another 5% to that increase. The bullish

Inhibikase Therapeutics Provides Interim Update on the '501' Bioequivalence Study of IkT-001Pro

Completed dosing of 3 of 4 planned cohorts; expect to complete study in the second quarter of 2023 BOSTON and ATLANTA, March 15, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or

Inhibikase Therapeutics Stock Turns Bullish After FDA Lifts Full Clinical Hold For Lead Candidate IkT-148009 ($IKT)

News, Press Releases

After the FDA lifted its full clinical hold on IkT-148009, Inhibikase Therapeutics, Inc. (NASDAQ:IKT) is back in play. Shares closed Monday over 12% higher on heavy volume, with investors sending the stock more than 19%

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.